JP2014510078A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510078A5 JP2014510078A5 JP2013557904A JP2013557904A JP2014510078A5 JP 2014510078 A5 JP2014510078 A5 JP 2014510078A5 JP 2013557904 A JP2013557904 A JP 2013557904A JP 2013557904 A JP2013557904 A JP 2013557904A JP 2014510078 A5 JP2014510078 A5 JP 2014510078A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- lymphoma
- cell
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 37
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 201000011510 cancer Diseases 0.000 claims 11
- 210000003719 b-lymphocyte Anatomy 0.000 claims 10
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 10
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 9
- 230000014509 gene expression Effects 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- RSNPAKAFCAAMBH-UHFFFAOYSA-N 3-(5-amino-2-methyl-4-oxoquinazolin-3-yl)piperidine-2,6-dione Chemical compound CC1=NC2=CC=CC(N)=C2C(=O)N1C1CCC(=O)NC1=O RSNPAKAFCAAMBH-UHFFFAOYSA-N 0.000 claims 5
- 206010060862 Prostate cancer Diseases 0.000 claims 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 5
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 claims 4
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 4
- 238000001574 biopsy Methods 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 239000000090 biomarker Substances 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims 2
- 102100028122 Forkhead box protein P1 Human genes 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 101001059893 Homo sapiens Forkhead box protein P1 Proteins 0.000 claims 2
- 101001131670 Homo sapiens PWWP domain-containing DNA repair factor 3A Proteins 0.000 claims 2
- 101000825182 Homo sapiens Transcription factor Spi-B Proteins 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 108010057466 NF-kappa B Proteins 0.000 claims 2
- 102000003945 NF-kappa B Human genes 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 2
- 239000003098 androgen Substances 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 238000012512 characterization method Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 210000001165 lymph node Anatomy 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- BVJRNKXVSYLNFD-UHFFFAOYSA-N 3-(5-amino-2-methyl-4-oxoquinazolin-3-yl)piperidine-2,6-dione;hydrochloride Chemical compound Cl.CC1=NC2=CC=CC(N)=C2C(=O)N1C1CCC(=O)NC1=O BVJRNKXVSYLNFD-UHFFFAOYSA-N 0.000 claims 1
- -1 5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl Chemical group 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010073128 Anaplastic oligodendroglioma Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 206010006143 Brain stem glioma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100024965 Caspase recruitment domain-containing protein 11 Human genes 0.000 claims 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010016935 Follicular thyroid cancer Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 101100219559 Homo sapiens CARD11 gene Proteins 0.000 claims 1
- 101000761179 Homo sapiens Caspase recruitment domain-containing protein 11 Proteins 0.000 claims 1
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- BGRDGMRNKXEXQD-UHFFFAOYSA-N Maleic hydrazide Chemical compound OC1=CC=C(O)N=N1 BGRDGMRNKXEXQD-UHFFFAOYSA-N 0.000 claims 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 claims 1
- 206010059282 Metastases to central nervous system Diseases 0.000 claims 1
- 101000687343 Mus musculus PR domain zinc finger protein 1 Proteins 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 1
- 229940123263 Phosphodiesterase 3 inhibitor Drugs 0.000 claims 1
- 229940123304 Phosphodiesterase 7 inhibitor Drugs 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 108010009975 Positive Regulatory Domain I-Binding Factor 1 Proteins 0.000 claims 1
- 102000009844 Positive Regulatory Domain I-Binding Factor 1 Human genes 0.000 claims 1
- 206010038019 Rectal adenocarcinoma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 102100022281 Transcription factor Spi-B Human genes 0.000 claims 1
- 208000037280 Trisomy Diseases 0.000 claims 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 150000003838 adenosines Chemical class 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 claims 1
- 229960002707 bendamustine Drugs 0.000 claims 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960004630 chlorambucil Drugs 0.000 claims 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims 1
- 238000011443 conventional therapy Methods 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 208000013210 hematogenous Diseases 0.000 claims 1
- 210000000777 hematopoietic system Anatomy 0.000 claims 1
- 208000029824 high grade glioma Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 201000010260 leiomyoma Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 201000011614 malignant glioma Diseases 0.000 claims 1
- 208000006178 malignant mesothelioma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 1
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 1
- 230000000683 nonmetastatic effect Effects 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000010198 papillary carcinoma Diseases 0.000 claims 1
- 201000002628 peritoneum cancer Diseases 0.000 claims 1
- 210000004786 perivascular cell Anatomy 0.000 claims 1
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 claims 1
- 239000002606 phosphodiesterase VII inhibitor Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 claims 1
- 238000010837 poor prognosis Methods 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 201000001281 rectum adenocarcinoma Diseases 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 201000009295 smoldering myeloma Diseases 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161451995P | 2011-03-11 | 2011-03-11 | |
| US61/451,995 | 2011-03-11 | ||
| US201161480272P | 2011-04-28 | 2011-04-28 | |
| US61/480,272 | 2011-04-28 | ||
| PCT/US2012/028498 WO2012125459A1 (en) | 2011-03-11 | 2012-03-09 | Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017009923A Division JP6348192B2 (ja) | 2011-03-11 | 2017-01-24 | ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンを用いる癌の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014510078A JP2014510078A (ja) | 2014-04-24 |
| JP2014510078A5 true JP2014510078A5 (enExample) | 2015-04-23 |
Family
ID=45876915
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013557904A Withdrawn JP2014510078A (ja) | 2011-03-11 | 2012-03-09 | ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンを用いる癌の治療方法 |
| JP2013557916A Expired - Fee Related JP6118273B2 (ja) | 2011-03-11 | 2012-03-09 | 免疫関連疾患及び炎症性疾患の治療における３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンの使用 |
| JP2016248598A Pending JP2017081959A (ja) | 2011-03-11 | 2016-12-22 | 免疫関連疾患及び炎症性疾患の治療における３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンの使用 |
| JP2017009923A Expired - Fee Related JP6348192B2 (ja) | 2011-03-11 | 2017-01-24 | ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンを用いる癌の治療方法 |
| JP2018103019A Withdrawn JP2018168159A (ja) | 2011-03-11 | 2018-05-30 | ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンを用いる癌の治療方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013557916A Expired - Fee Related JP6118273B2 (ja) | 2011-03-11 | 2012-03-09 | 免疫関連疾患及び炎症性疾患の治療における３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンの使用 |
| JP2016248598A Pending JP2017081959A (ja) | 2011-03-11 | 2016-12-22 | 免疫関連疾患及び炎症性疾患の治療における３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンの使用 |
| JP2017009923A Expired - Fee Related JP6348192B2 (ja) | 2011-03-11 | 2017-01-24 | ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンを用いる癌の治療方法 |
| JP2018103019A Withdrawn JP2018168159A (ja) | 2011-03-11 | 2018-05-30 | ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンを用いる癌の治療方法 |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US8906932B2 (enExample) |
| EP (3) | EP2683383B1 (enExample) |
| JP (5) | JP2014510078A (enExample) |
| KR (2) | KR20140025374A (enExample) |
| CN (3) | CN103561744A (enExample) |
| AR (1) | AR085651A1 (enExample) |
| AU (4) | AU2012229300B2 (enExample) |
| BR (2) | BR112013023277A2 (enExample) |
| CA (2) | CA2829592A1 (enExample) |
| CY (1) | CY1117430T1 (enExample) |
| DK (1) | DK2683384T3 (enExample) |
| EA (2) | EA201691939A1 (enExample) |
| ES (2) | ES2562332T3 (enExample) |
| HR (1) | HRP20160056T1 (enExample) |
| HU (1) | HUE027481T2 (enExample) |
| IL (2) | IL227990B (enExample) |
| MX (2) | MX2013010217A (enExample) |
| NI (2) | NI201300081A (enExample) |
| PH (2) | PH12013501820A1 (enExample) |
| PL (1) | PL2683384T3 (enExample) |
| PT (1) | PT2683384E (enExample) |
| RS (1) | RS54553B1 (enExample) |
| RU (3) | RU2013145556A (enExample) |
| SG (2) | SG192947A1 (enExample) |
| SI (1) | SI2683384T1 (enExample) |
| SM (1) | SMT201600034B (enExample) |
| TW (2) | TW201700100A (enExample) |
| WO (2) | WO2012125459A1 (enExample) |
| ZA (2) | ZA201306148B (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2420498T (lt) | 2006-09-26 | 2017-10-25 | Celgene Corporation | 5-pakeistieji chinazolinono dariniai, kaip priešvėžiniai agentai |
| EP2436387B1 (en) | 2009-05-25 | 2018-07-25 | Celgene Corporation | Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex |
| EA026100B1 (ru) | 2011-03-11 | 2017-03-31 | Селджин Корпорейшн | Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2,6-диона и их фармацевтические композиции и применение |
| WO2012135299A1 (en) | 2011-03-28 | 2012-10-04 | Deuteria Pharmaceuticals Inc | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| MX353482B (es) * | 2011-04-29 | 2018-01-16 | Celgene Corp | Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor. |
| CA3136093C (en) | 2012-06-29 | 2025-07-08 | Celgene Corporation | METHODS FOR DETERMINING THE EFFICACY OF A DRUG USING PROTEINS ASSOCIATED WITH CEREBLON |
| JP6347782B2 (ja) * | 2012-08-09 | 2018-06-27 | セルジーン コーポレイション | ３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンを使用する癌の治療方法 |
| US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
| WO2014039421A1 (en) | 2012-09-04 | 2014-03-13 | Celgene Corporation | Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof |
| CA2884103A1 (en) * | 2012-09-10 | 2014-03-13 | Celgene Corporation | Methods for the treatment of locally advanced breast cancer |
| US9540340B2 (en) | 2013-01-14 | 2017-01-10 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same |
| US9290475B2 (en) | 2013-03-14 | 2016-03-22 | Deuterx, Llc | 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same |
| MX368286B (es) * | 2013-04-17 | 2019-09-27 | Signal Pharm Llc | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer. |
| EP2986321A1 (en) * | 2013-04-17 | 2016-02-24 | Signal Pharmaceuticals, LLC | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer |
| ES2645944T3 (es) * | 2013-05-01 | 2017-12-11 | Celgene Corporation | Síntesis de la 3-(5-amino-2-metil-4-oxoquinazolín-3(4H)-il)piperidina-2,6-diona |
| WO2014179661A1 (en) | 2013-05-03 | 2014-11-06 | Celgene Corporation | Methods for treating cancer using combination therapy |
| WO2015077058A2 (en) | 2013-11-08 | 2015-05-28 | The Broad Institute, Inc. | Compositions and methods for selecting a treatment for b-cell neoplasias |
| BR112016012795A2 (pt) * | 2013-12-06 | 2017-08-08 | Celgene Corp | Métodos para a determinação da eficácia do fármaco para o tratamento de linfoma difuso de grandes células b, mieloma múltiplo e cânceres mieloides |
| US20150196562A1 (en) * | 2014-01-15 | 2015-07-16 | Celgene Corporation | Formulations of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
| WO2015200795A1 (en) | 2014-06-27 | 2015-12-30 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases |
| AU2015287694A1 (en) * | 2014-07-11 | 2017-02-02 | Celgene Corporation | Combination therapy for cancer |
| SMT202300081T1 (it) | 2014-08-22 | 2023-05-12 | Celgene Corp | Metodi di trattamento di mieloma multiplo con composti immunomodulatori in combinazione con anticorpi |
| CN113559075A (zh) | 2014-11-17 | 2021-10-29 | 康泰科思特生物制药公司 | 奥那司酮延长释放组合物和方法 |
| TW201642857A (zh) * | 2015-04-06 | 2016-12-16 | 西建公司 | 以組合療法治療肝細胞癌 |
| EP3316888A1 (en) * | 2015-07-02 | 2018-05-09 | Celgene Corporation | Combination therapy for treatment of hematological cancers and solid tumors |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| MX2018002487A (es) * | 2015-08-27 | 2018-06-15 | Celgene Corp | Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinalozin-3-il)-pipe ridin-2,6-diona. |
| EP3347717A4 (en) | 2015-09-11 | 2019-06-05 | The Brigham and Women's Hospital, Inc. | PROCESS FOR CHARACTERIZING THE RESISTANCE TO CEREBLON MODULATORS |
| CA2998924A1 (en) | 2015-09-25 | 2017-03-30 | Context Biopharma Inc. | Methods of making onapristone intermediates |
| BR112018010964A2 (pt) * | 2015-12-02 | 2018-12-04 | Celgene Corp | terapia de ciclo usando 3-(5-amino-2-methil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona |
| JP2019503353A (ja) | 2015-12-15 | 2019-02-07 | コンテキスト・バイオファーマ・インコーポレイテッド | 非晶質オナプリストン組成物およびそれを作製する方法 |
| US10830762B2 (en) | 2015-12-28 | 2020-11-10 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
| EP3404024B1 (en) | 2016-01-14 | 2020-11-18 | Kangpu Biopharmaceuticals, Ltd. | Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications |
| US11395820B2 (en) * | 2016-03-16 | 2022-07-26 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Small molecules against cereblon to enhance effector t cell function |
| US20180148471A1 (en) | 2016-11-30 | 2018-05-31 | Arno Therapeutics, Inc. | Methods for onapristone synthesis dehydration and deprotection |
| US20180258064A1 (en) * | 2017-03-07 | 2018-09-13 | Celgene Corporation | Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
| IL271491B2 (en) * | 2017-06-22 | 2023-09-01 | Celgene Corp | Treatment of carcinoma of the liver characterized by hepatitis b virus infection |
| WO2019077968A1 (en) | 2017-10-18 | 2019-04-25 | Canon Kabushiki Kaisha | PACKAGING CONTAINER AND PACKAGE |
| CA3094988A1 (en) * | 2018-03-30 | 2019-10-03 | Biotheryx, Inc. | Thienopyrimidinone compounds |
| SG11202012464WA (en) | 2018-07-11 | 2021-01-28 | H Lee Moffitt Cancer Center And Research Institute Inc | Dimeric immuno-modulatory compounds against cereblon-based mechanisms |
| JP7323603B2 (ja) * | 2018-09-07 | 2023-08-08 | メッドシャイン ディスカバリー インコーポレイテッド | 三環式縮合フラン置換ピペリジンジオン系化合物 |
| US11529339B2 (en) | 2018-10-01 | 2022-12-20 | Celgene Corporation | Combination therapy for the treatment of cancer |
| KR102429562B1 (ko) | 2019-03-22 | 2022-08-05 | 재단법인 아산사회복지재단 | 간세포암 진단용 바이오마커 세레브론 및 이에 특이적인 신규한 단일클론항체 |
| WO2021198188A1 (en) * | 2020-03-30 | 2021-10-07 | Enyo Pharma | Quinazolinone derivatives and uses thereof for treating a cancer |
| TW202416995A (zh) * | 2022-08-16 | 2024-05-01 | 比利時商艾托斯比利時公司 | 用於治療與至少一種抗體分泌細胞標記物之表現相關的疾病的腺苷受體拮抗劑及其組合物 |
| CN118844365A (zh) * | 2024-06-26 | 2024-10-29 | 华南理工大学 | 一种化疗诱发的血液毒性斑马鱼模型及其应用 |
| CN119161336B (zh) * | 2024-07-24 | 2025-09-05 | 四川大学 | 一种作为Blimp1抑制剂的小分子化合物及其用途 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| ES8702440A1 (es) | 1984-10-04 | 1986-12-16 | Monsanto Co | Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa. |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| WO1997001331A2 (en) | 1995-06-27 | 1997-01-16 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| EP0839525B1 (en) | 1996-10-31 | 2004-08-04 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| DE69719367T2 (de) | 1996-12-20 | 2003-10-16 | Takeda Chemical Industries, Ltd. | Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| JP2004526419A (ja) | 2000-10-16 | 2004-09-02 | フィロス インク． | 抗体模倣物および他の結合タンパク質のためのタンパク質骨格 |
| EP1411970B1 (en) * | 2000-12-06 | 2007-04-18 | Applied Research Systems ARS Holding N.V. | Use of sarp-1 for the treatment and/or prevention of scleroderma |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2002088171A2 (en) | 2001-04-26 | 2002-11-07 | Avidia Research Institute | Combinatorial libraries of monomer domains |
| US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US20060234299A1 (en) | 2004-11-16 | 2006-10-19 | Avidia Research Institute | Protein scaffolds and uses thereof |
| US20080051379A1 (en) | 2004-12-01 | 2008-02-28 | Trustees Of Boston University | Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms |
| LT2420498T (lt) * | 2006-09-26 | 2017-10-25 | Celgene Corporation | 5-pakeistieji chinazolinono dariniai, kaip priešvėžiniai agentai |
| GB0709092D0 (en) * | 2007-05-11 | 2007-06-20 | Borrebaeck Carl | Diagnosis and method of disease |
| JP5637852B2 (ja) * | 2007-09-26 | 2014-12-10 | セルジーン コーポレイション | ６、７又は８置換キナゾリノン誘導体並びにそれらを含有する組成物及びそれらを使用する方法 |
| CA2707729A1 (en) * | 2007-12-07 | 2009-06-18 | Celgene Corporation | Biomarkers for monitoring the treatment by quinazolinone compounds |
| EP2436387B1 (en) | 2009-05-25 | 2018-07-25 | Celgene Corporation | Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex |
| MX353482B (es) * | 2011-04-29 | 2018-01-16 | Celgene Corp | Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor. |
-
2012
- 2012-03-09 PT PT127108363T patent/PT2683384E/pt unknown
- 2012-03-09 SI SI201230451A patent/SI2683384T1/sl unknown
- 2012-03-09 PL PL12710836T patent/PL2683384T3/pl unknown
- 2012-03-09 SG SG2013064373A patent/SG192947A1/en unknown
- 2012-03-09 CN CN201280022778.1A patent/CN103561744A/zh active Pending
- 2012-03-09 TW TW105111258A patent/TW201700100A/zh unknown
- 2012-03-09 AR ARP120100782 patent/AR085651A1/es unknown
- 2012-03-09 HU HUE12710836A patent/HUE027481T2/en unknown
- 2012-03-09 HR HRP20160056TT patent/HRP20160056T1/hr unknown
- 2012-03-09 CN CN201280022744.2A patent/CN103561743A/zh active Pending
- 2012-03-09 MX MX2013010217A patent/MX2013010217A/es active IP Right Grant
- 2012-03-09 US US13/417,088 patent/US8906932B2/en not_active Expired - Fee Related
- 2012-03-09 EP EP12710411.5A patent/EP2683383B1/en not_active Not-in-force
- 2012-03-09 BR BR112013023277A patent/BR112013023277A2/pt not_active IP Right Cessation
- 2012-03-09 BR BR112013023280A patent/BR112013023280A2/pt not_active IP Right Cessation
- 2012-03-09 RS RS20160067A patent/RS54553B1/sr unknown
- 2012-03-09 CN CN201710232755.8A patent/CN107375293A/zh active Pending
- 2012-03-09 EA EA201691939A patent/EA201691939A1/ru unknown
- 2012-03-09 ES ES12710836.3T patent/ES2562332T3/es active Active
- 2012-03-09 WO PCT/US2012/028498 patent/WO2012125459A1/en not_active Ceased
- 2012-03-09 CA CA 2829592 patent/CA2829592A1/en not_active Abandoned
- 2012-03-09 WO PCT/US2012/028538 patent/WO2012125475A1/en not_active Ceased
- 2012-03-09 PH PH1/2013/501820A patent/PH12013501820A1/en unknown
- 2012-03-09 KR KR20137026403A patent/KR20140025374A/ko not_active Ceased
- 2012-03-09 JP JP2013557904A patent/JP2014510078A/ja not_active Withdrawn
- 2012-03-09 AU AU2012229300A patent/AU2012229300B2/en not_active Ceased
- 2012-03-09 RU RU2013145556/15A patent/RU2013145556A/ru not_active Application Discontinuation
- 2012-03-09 MX MX2013010153A patent/MX2013010153A/es active IP Right Grant
- 2012-03-09 KR KR20137026402A patent/KR20140019364A/ko not_active Withdrawn
- 2012-03-09 EA EA201391319A patent/EA201391319A1/ru unknown
- 2012-03-09 RU RU2017120977A patent/RU2017120977A/ru not_active Application Discontinuation
- 2012-03-09 SG SG2013066840A patent/SG193320A1/en unknown
- 2012-03-09 EP EP15197498.7A patent/EP3025715A1/en not_active Withdrawn
- 2012-03-09 RU RU2013145524/15A patent/RU2013145524A/ru not_active Application Discontinuation
- 2012-03-09 EP EP12710836.3A patent/EP2683384B1/en active Active
- 2012-03-09 CA CA 2829593 patent/CA2829593A1/en not_active Abandoned
- 2012-03-09 ES ES12710411.5T patent/ES2659205T3/es active Active
- 2012-03-09 US US13/984,833 patent/US20140148473A1/en not_active Abandoned
- 2012-03-09 PH PH1/2013/501837A patent/PH12013501837A1/en unknown
- 2012-03-09 AU AU2012229316A patent/AU2012229316B2/en not_active Ceased
- 2012-03-09 TW TW101108231A patent/TWI542349B/zh not_active IP Right Cessation
- 2012-03-09 JP JP2013557916A patent/JP6118273B2/ja not_active Expired - Fee Related
- 2012-03-09 DK DK12710836.3T patent/DK2683384T3/da active
-
2013
- 2013-08-15 ZA ZA2013/06148A patent/ZA201306148B/en unknown
- 2013-08-15 IL IL227990A patent/IL227990B/en active IP Right Grant
- 2013-08-21 ZA ZA2013/06305A patent/ZA201306305B/en unknown
- 2013-09-01 IL IL228230A patent/IL228230A/en not_active IP Right Cessation
- 2013-09-09 NI NI201300081A patent/NI201300081A/es unknown
- 2013-09-09 NI NI201300082A patent/NI201300082A/es unknown
-
2014
- 2014-11-05 US US14/533,941 patent/US20150126538A1/en not_active Abandoned
-
2016
- 2016-01-12 US US14/993,998 patent/US20160136167A1/en not_active Abandoned
- 2016-02-02 CY CY20161100088T patent/CY1117430T1/el unknown
- 2016-02-09 SM SM201600034T patent/SMT201600034B/xx unknown
- 2016-12-22 JP JP2016248598A patent/JP2017081959A/ja active Pending
-
2017
- 2017-01-24 JP JP2017009923A patent/JP6348192B2/ja not_active Expired - Fee Related
- 2017-02-22 US US15/439,879 patent/US20170165266A1/en not_active Abandoned
- 2017-04-11 US US15/484,850 patent/US20180055844A1/en not_active Abandoned
- 2017-06-28 AU AU2017204402A patent/AU2017204402A1/en not_active Abandoned
- 2017-08-04 AU AU2017210633A patent/AU2017210633A1/en not_active Abandoned
-
2018
- 2018-05-30 JP JP2018103019A patent/JP2018168159A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014510078A5 (enExample) | ||
| RU2013145524A (ru) | Способ лечения рака с использованием 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2, 6-диона | |
| Dancsok et al. | Advances in sarcoma diagnostics and treatment | |
| Issa et al. | Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma | |
| Mao et al. | Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents | |
| Riely et al. | EGFR: the paradigm of an oncogene-driven lung cancer | |
| Pérez-Galán et al. | Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era | |
| Asghar et al. | The history and future of targeting cyclin-dependent kinases in cancer therapy | |
| Iqbal et al. | Imatinib: a breakthrough of targeted therapy in cancer | |
| Easton et al. | mTOR and cancer therapy | |
| Tsai et al. | A multikinase and DNA-PK inhibitor combination immunomodulates melanomas, suppresses tumor progression, and enhances immunotherapies | |
| Kung et al. | Chemogenetic evaluation of the mitotic kinesin CENP-E reveals a critical role in triple-negative breast cancer | |
| AU2018341571A1 (en) | Therapeutic methods relating to HSP90 inhibitors | |
| MX2013012564A (es) | Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor. | |
| AU2010314287A1 (en) | Combinations of a PI3K inhibitor and a MEK inhibitor | |
| CA2850175C (en) | Biomarkers for predicting sensitivity to cancer treatments | |
| JP2021098750A (ja) | がんを治療するためのｍｄｍ２阻害剤の投与計画 | |
| WO2016170163A1 (en) | Substituted quinoxalines and benzotriazine p70s6 kinase inhibitors | |
| WO2021138215A1 (en) | Treatment of cancer with cdk12/13 inhibitors | |
| Frett et al. | Therapeutic Melting Pot of Never in Mitosis Gene A Related Kinase 2 (Nek2): A Perspective on Nek2 as an Oncology Target and Recent Advancements in Nek2 Small Molecule Inhibition: Miniperspective | |
| KR20080004495A (ko) | 암을 치료하기 위한 조합물, 방법 및 조성물 | |
| Ryspayeva et al. | Signaling pathway dysregulation in breast cancer | |
| EP3356348A1 (en) | 2-aminoquinazoline derivatives as p70s6 kinase inhibitors | |
| Quintás‐Cardama et al. | Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis | |
| Lawasut et al. | Decoding the pathophysiology and the genetics of multiple myeloma to identify new therapeutic targets |